Exelead is a CDMO
dedicated to the
development and
commercialization of
therapeutics to
treat
life-threatening
diseases.
Exelead’s core
technologies focus
on the manufacture
of sterile drug
products
specializing in
liposomal and
PEGylation
formulation
technologies.
Exelead has
development
capabilities that
can be utilized to
improve drug
delivery and drug
product
characterization.
The Indianapolis,
Indiana
manufacturing
facility produces
proprietary
parenteral
pharmaceuticals for
oncology and enzyme
replacement
treatment, as well
as for the treatment
of numerous
infectious diseases.
Our staff is a
balance of:
chemists, chemical
engineers,
microbiologists, and
pharmaceutical
manufacturing
experts. Senior
Exelead management
is a mix of seasoned
executives from the
pharmaceutical and
biotechnology
industries. Exelead
is a wholly owned
subsidiary of
Essetefin SpA (Rome,
Italy) and is led by
John Rigg, Vice
President and
General Manager.